In line with this, a novel breast cancer signature consisting of CRGs such as PGK1, SLC52A2, and RAD23B has shown potential for prognosis prediction, with RAD23B emerging as a promising target linked to disease progression and drug resistance (Song et al., 2022). The gene discussed is RAD23B; the disease is breast carcinoma.